Gingival Overgrowth Among Patients Medicated With Cyclosporin A and Tacrolimus Undergoing Renal Transplantation: A Prospective Study

Paixão, Caroline Gomes; Sekiguchi, Ricardo Takiy; Saraiva, Luciana; Pannuti, Cláudio Mendes; Silva, Hélio T.; Medina‐Pestana, José Osmar; Romito, Giuseppe Alexandre

doi:10.1902/jop.2010.100368

Cited by 27 publications

(26 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also nephrotoxic, but it results in much less severe hypertension and hypertrichosis. [2432] Various studies have demonstrated less frequent association of gingival overgrowth with the use of tacrolimus than with cyclosporin. [3334] Synergistic effects have been reported when cyclosporin is administered concurrently with calcium channel blockers of dihydropyridine derivatives.…”

Section: Drugs Which Cause Gingival Overgrowthmentioning

confidence: 99%

Drug-induced gingival overgrowth: The nemesis of gingiva unravelled

Bharti¹,

Bansal²

2013

J Indian Soc Periodontol

View full text Add to dashboard Cite

Drug-induced gingival overgrowth or enlargement manifests as abnormal growth of the gingiva due to an adverse drug reaction (ADR) in patients treated with anticonvulsants, immunosuppressants, and calcium channel blockers. As gingival enlargement develops, it affects the normal oral hygiene practice and may interfere with masticatory functions. It gradually becomes a source of pain and the condition often leads to disfiguration. Within the group of patients that develop this unwanted effect, there appears to be variability in the extent and severity of the gingival changes. It would seem pertinent to identify and explore possible risk factors and relating them with the treatment plan. This article throws light on respective drugs and their association with gingival overgrowth and approaches to treatment based on current knowledge and investigative observations.

show abstract

Section: Drugs Which Cause Gingival Overgrowthmentioning

confidence: 99%

Drug-induced gingival overgrowth: The nemesis of gingiva unravelled

Bharti¹,

Bansal²

2013

J Indian Soc Periodontol

View full text Add to dashboard Cite

show abstract

“…DIGO incidence in patients under ciclosporin is more than double than that in patients using tacrolimus or sirolimus. The use of calcium channel blockers has a multiplicative effect in promoting DIGO in patients on ciclosporin (Greenberg et al , 2008; Shiboski et al , 2009b; Cota et al , 2010; Paixão et al , 2011).…”

Section: Drug‐induced Gingival Overgrowthmentioning

confidence: 99%

“…Drug‐induced gingival overgrowth prevalence and severity are assessed through full‐mouth alginate impressions (Seymour et al , 1985). Prevalence in transplant recipients on ciclosporin is high (20–76%) (Greenberg et al , 2008; Shiboski et al , 2009b; Cota et al , 2010; Paixão et al , 2011), markedly lower in the absence of gingivitis (Aimetti et al , 2005, 2008; Kara et al , 2007). Some thus attribute a causative role to dental plaque, and others even consider DIGO a risk factor for dental caries development (Doufexi et al , 2005; Nakib and Ashrafi, 2011), but observational studies fail to support such hypotheses, showing no significant differences between transplant patients with DIGO and controls in parameters such as oral hygiene, gingivitis, and caries (al‐Sarheed et al , 2000; Sheehy et al , 2000; al Nowaiser et al , 2004).…”

Section: Drug‐induced Gingival Overgrowthmentioning

confidence: 99%

Orofacial diseases in solid organ and hematopoietic stem cell transplant recipients

Petti¹,

Polimeni

Berloco

et al. 2012

Oral Diseases

View full text Add to dashboard Cite

show abstract

“…Thomason et al 15 found a GO prevalence of 47.82% (scores ≥ 30%) when CsA and nifedipine were used in combination, and 37.5% for CsA alone. The results reported by de Oliveira Costa et al 8 and Paixão et al 19 in Brazil revealed significant GO (score ≥ 30%) in 38.1% and 17.4% of CsA-treated patients, respectively. Our study found a lower percentage (8%) of patients using the same GO cut-off; when the cut-off point was lowered to > 10%, the GO prevalence was 17.5%.…”

Section: Discussionmentioning

confidence: 78%

Low prevalence of gingival overgrowth associated to new imunossupressive protocols with cyclosporin

et al. 2011

View full text Add to dashboard Cite

Gingival overgrowth (GO) is a frequent finding in patients treated with cyclosporine (CsA). This study investigated the prevalence and severity of GO in patients who received kidney transplant and CsA therapy, as well as associations with pharmacological and clinical factors. This cross-sectional study included 63 kidney transplant recipients who were treated with CsA in a university hospital. Demographic, pharmacological, and periodontal data were collected. The primary variable was GO. Independent sample t-and chi-square tests were used to compare means in groups with versus without GO. The response rate was 86.3%. Overall, 40% of patients had some degree of GO. Eleven individuals presented GO scores > 10%, and 5 individuals reached 30%. The mean GO percentage was low (6.79 ± 15.83). Patients that were concurrently under nifedipine treatment showed a non-significant trend toward a greater prevalence of GO. Mean CsA dosage and serum levels were 3.20 ± 0.94 mg/kg/d and 156.12 ± 162.75 ng/mL, respectively. There were no statistically significant differences between patients with versus without GO nor between the groups receiving nifedipine, no drug, or verapamil. The GO prevalence and severity rates were lower than those reported in previous studies and seemed to be independent of drug interactions.

show abstract

Gingival Overgrowth Among Patients Medicated With Cyclosporin A and Tacrolimus Undergoing Renal Transplantation: A Prospective Study

Abstract: Although there was no statistical difference in the incidences of clinically significant GO after 180 days of immunosuppressive therapy, it was observed that GO occurred later in the Tcr group, and the severity of GO in this group was lower than in patients who used CsA.

Cited by 27 publications

References 31 publications

Drug-induced gingival overgrowth: The nemesis of gingiva unravelled

Drug-induced gingival overgrowth: The nemesis of gingiva unravelled

Orofacial diseases in solid organ and hematopoietic stem cell transplant recipients

Low prevalence of gingival overgrowth associated to new imunossupressive protocols with cyclosporin

Contact Info

Product

Resources

About